Erratablad till avhandling:
Pierre de Flon (2018) Treatment with the monoclonal antibody rituximab in Multiple Sclerosis—a study based on an academic clinical trial.
Institutionen för Farmakologi och Klinisk Neurovetenskap, Umeå universitet.
ISSN 0346-6612

Korrigeringar

# Sid iii, Abstract; Results: "Both the mean number of Gd enhancing lesions (0.03 vs 0.36, p=0.029) and the number of new or enlarged T2 lesions were reduced (0.01 vs 0.28, p=0.01).” ska vara

"Both the mean number of Gd enhancing lesions (0.36 vs 0.03, p=0.029) and the number of new or enlarged T2 lesions were reduced (0.28 vs 0.01, p=0.01)"

# Sid vii: I "Abbreviations" saknas "SPMS- secondary progressive MS"

# Sid 1: "It was clarified that the phenotype is dynamic and that the classification for a specific patient may change over time, e.g. RRMS may develop into SPMS” ska vara

"It was clarified that the phenotype is dynamic and that the classification for a specific patient may change over time, e.g. RRMS may develop into secondary progressive MS (SPMS).”
